Report: European injectable drug delivery market poised to soar

The European injectable drug delivery technologies market was already worth a substantial $6.8 billion in 2012. But that number should soar to $12.4 billion by 2017, Markets and Markets estimates in a new report. Why the expansion? The report's authors see favorable reimbursement policies on injectable drugs and devices, improving technology and a surge of new biologics as helping to drive the trend. Higher rates of cancer and diabetes in Europe are also spurring market growth, the report concludes. While Germany accounted for the largest market share for injectable drug-delivery technologies in 2012, France is the fastest growing region. Item

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.